Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-01), Medico Remedies's 14-Day RSI is 45.83.
The industry rank for Medico Remedies's 14-Day RSI or its related term are showing as below:
BOM:540937's 14-Day RSI is ranked better than 64.95% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 49.44
vs BOM:540937: 45.83
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Medico Remedies 14-Day RSI Related Terms
BOM:540937 vs ZTS: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medico Remedies 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Medico Remedies's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medico Remedies (BOM:540937) has a 14-Day RSI of 45.83 as of Sep. 01, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Medico Remedies and its competitors. According to the industry distribution chart, Medico Remedies ranks #367 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 35.1%.
Is Medico Remedies' 14-Day RSI too high?
Medico Remedies' current 14-Day RSI is 45.83. The Drug Manufacturers industry median 14-Day RSI is 49.44. Medico Remedies' value of 45.83 is 7.3% below this industry median. Based on the distribution chart, Medico Remedies ranks #367 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medico Remedies has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' 14-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medico Remedies ranks #367 out of 1047 companies for 14-Day RSI. This puts Medico Remedies in the upper half of its industry. The industry median 14-Day RSI is 49.44. Medico Remedies' value of 45.83 is 7.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 49.44, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medico Remedies's current 14-Day RSI of 45.83 is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Medico Remedies and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 49.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medico Remedies's current 14-Day RSI is 45.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (BOM:540937) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹77.96, compared to a current price of ₹42.50 — trading 45.5% below its estimated fair value. The current 14-Day RSI is 45.83 and 7.3% below the Drug Manufacturers industry median of 49.44. Medico Remedies' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Medico Remedies (BOM:540937), the current 14-Day RSI is 45.83 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medico Remedies (BOM:540937) Overvalued in 2026?
Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued.
The current stock price of ₹42.50 is trading 45.5% below its estimated GF Value™ of ₹77.96.
GuruFocus considers Medico Remedies to be Significantly Undervalued.
Key valuation signals for BOM:540937:
14-Day RSI: 45.83
GF Value™: ₹77.96 vs. price of ₹42.50 (45.5% below fair value)
Industry Position: 7.3% below the Drug Manufacturers median (#367 of 1047)
No single metric tells the full story. See the BOM:540937 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
85GF Score
Get the complete analysis for BOM:540937
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540937 has been successfully added to your 
